Pacira BioSciences, Inc. Total Liabilities
Pacira BioSciences, Inc. total liabilities. Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has total liabilities worth $572.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PCRX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pacira BioSciences, Inc. (2008–2025)
Total liabilities of Pacira BioSciences, Inc. from 2008 to 2025. This chart illustrates how Pacira BioSciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Pacira BioSciences, Inc. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Pacira BioSciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Pacira BioSciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
China | CN¥575.08 Million |
|
Guomai Technologies Inc
SHE:002093
|
China | CN¥620.98 Million |
|
Elecon Engineering Company Limited
NSE:ELECON
|
India | Rs-23.06 Billion |
|
HUANLEJIA Food Group Co. Ltd.
SHE:300997
|
China | CN¥707.74 Million |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥1.83 Billion |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs2.75 Billion |
|
Mersen SA
PA:MRN
|
France | €914.60 Million |
|
Jiujiang Shanshui Technology Co.Ltd
SHE:301190
|
China | CN¥209.60 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Pacira BioSciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Pacira BioSciences, Inc.'s balance sheet.
Liquidity & Leverage Metrics
Pacira BioSciences, Inc. Total Liabilities Ratios Explained
Pacira BioSciences, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacira BioSciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual total liabilities of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $571.81 Million | -26.23% |
| 2024-12-31 | $775.17 Million | +10.07% |
| 2023-12-31 | $704.26 Million | -22.28% |
| 2022-12-31 | $906.19 Million | -32.62% |
| 2021-12-31 | $1.34 Billion | +105.39% |
| 2020-12-31 | $654.83 Million | +37.53% |
| 2019-12-31 | $476.12 Million | +29.34% |
| 2018-12-31 | $368.13 Million | +5.51% |
| 2017-12-31 | $348.89 Million | +102.27% |
| 2016-12-31 | $172.49 Million | +0.74% |
| 2015-12-31 | $171.23 Million | +10.52% |
| 2014-12-31 | $154.93 Million | +20.50% |
| 2013-12-31 | $128.57 Million | +178.30% |
| 2012-12-31 | $46.20 Million | -29.17% |
| 2011-12-31 | $65.22 Million | -43.26% |
| 2010-12-31 | $114.94 Million | +71.81% |
| 2009-12-31 | $66.90 Million | +55.40% |
| 2008-12-31 | $43.05 Million | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more